Novel Therapeutic Approaches for Cystic Fibrosis
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 20 May 2024 | Viewed by 1036
Special Issue Editors
Interests: biochemistry and computational chemistry; cystic fibrosis; ferroptosis; lipid peroxidation; neurodegeneration; cancer reasearch; protein phoshorylation; signal transduction; drug design and development; drug repurposing
Special Issues, Collections and Topics in MDPI journals
Interests: protein kinases; protein phosphorylation; kinase; signal transduction; apoptosis; cell signaling; signaling; cancer cell signaling; cellular biochemistry; cancer research; cystic fibrosis; nanotechnologies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Mutations in the gene-encoding CFTR (Cystic Fibrosis Transmembrane Conductance Regulator), a chloride and bicarbonate channel located on the apical membrane of epithelial cells, trigger Cystic Fibrosis (CF), a severe, rare disease. The primary cause of death from CF is respiratory failure, driven by infections, prolonged inflammation, and damage to the lungs. The complex and varied clinical symptoms affecting several organs, including the pancreas, liver, kidneys, and intestines, further emphasize the significant contribution of this single protein to the pathogenesis of CF. Around 2000 mutations in the CFTR protein have been discovered, classified into six categories. Most CF patients bear the F508del class II mutation, which causes CFTR entrapment in the endoplasmic reticulum and its premature degradation before reaching the plasma membrane. Even though many drugs have been approved and clinical care ensures a steady improvement in the quality of life of CF patients, the development of new therapies not limited to the most common mutations but also targeting other pathological CFTR mutants remains a challenge. With this Special Issue, entitled "Novel Therapeutic Approaches for Cystic Fibrosis", we would like to invite authors to contribute review articles or original research articles that shed light on recent advances in the discovery of new therapeutic perspectives for CF. Contributions can include, but are not limited to, new therapies targeting orphan CFTR mutations, innovative treatments that could control CF symptoms or prevent CF complications, and studies elucidating the mechanisms of action of promising new molecules or suggesting alternative approaches and pharmaceutical strategies in the management of CF.
Dr. Giorgio Cozza
Dr. Andrea Venerando
Dr. Ilaria Artusi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cystic fibrosis
- CFTR mutations
- pathophysiology
- inflammation
- infection
- high-throughput screening
- drug development
- therapies
- treatments
- clinical trials
